Conventional External Beam Radiation Therapy and High Dose Rate Afterloading Brachytherapy as a Boost for Patients Olderthan 70 years
Appl. cancer res
; 25(3): 130-136, July-Sept. 2005.
Article
in En
| LILACS, Inca
| ID: lil-442310
Responsible library:
BR30.1
ABSTRACT
The treatment options for patients with non metastatic prostate cancer range from observation, radical prostatectomy, radiationtherapy, hormonal therapy to various combination of some to all of them. Objective:
We evaluated the impact on biochemicalcontrol of disease (bNED), acute and late intestinal (GI) and urological (GU) morbidity for a group of patients older than 70years presenting initial or locally advanced prostate cancer treated with fractionated high dose rate brachytherapy (HDRB) asa boost to conventional external beam radiation therapy (RT) at the Department of Radiation Oncology from Hospital do CâncerA. C. Camargo, São Paulo, Brazil.Methods:
A total of 56 patients older than 70 were treated from March, 1997 to June,2002. All patients had prior to HDRB a course of RT to a median dose of 45 Gy. HDRB doses ranged from 16 Gy to 20 Gy, givenin 4 fractions.Results:
The median age of the patients was 74.4 years (range 70-83) and the median follow-up 33 months(range 24 to 60). The 5-year actuarial bNED rate was 77%. Acute GU and GI morbidity G1-2 were seen in 17.8% and 7.1% ofpatients, respectively. Late G1 or G2 GU morbidity was seen in 10.7% of the patients, while late G3 morbidity was observedin 7.1% of the patients, represented by urethral strictures.Conclusion:
this group of patients had similar bNED rates whencompared to literature, with acceptable morbidity rates.
Full text:
1
Index:
LILACS
Main subject:
Prostatic Neoplasms
/
Brachytherapy
/
Morbidity
/
Treatment Outcome
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
Appl. cancer res
Journal subject:
NEOPLASIAS
Year:
2005
Type:
Article